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We congratulate Leu et al. on their recent publication in this
journal,1 describing a vancomycin dosing nomogram that targets
trough concentrations with greater accuracy. We wish to share
data that support further consideration of this dosing strategy.
In order to improve efﬁcacy, target vancomycin trough
concentrations have increased over time.2–4 Due to variable
pharmacokinetics, a signiﬁcant proportion of levels fall outside
target concentration ranges,5 placing patients at risk of treatment
failure or toxicity.
Although the Australian Therapeutic Guidelines recom-
mended a target trough range of 10–20 mg/l from 2006 to
2009,2 and of 12–18 mg/l from 2010,3 our hospital guidelines
have recommended targets of 15–25 mg/l for serious infections
since 2007. We retrieved all measurable inpatient serum
vancomycin concentrations performed during 2006–2012 at
our 720-bed teaching hospital in Western Australia. Levels that
were taken at <8 h or at an unknown time since the last dose
were excluded. Serum creatinine concentrations were retrieved
and nephrotoxicity deﬁned as a 50% rise during therapy. We
analyzed 13 182 inpatient vancomycin levels from 3353
patients. Our observations revealed that since 2007, 32.4% of
levels were below and 19.3% above the local target range.
Figure 1 demonstrates temporal trends for proportions of
vancomycin levels >15, 20, or 25 mg/l. Overall, 37.7% of trough
levels exceeded 20 mg/l—a potential risk factor for nephrotoxi-
city.6 Nephrotoxicity was calculated from patients who had two
or more serum creatinine levels recorded. Of these patients,
nephrotoxicity occurred in 279 patients (12.8%), but theFigure 1. Trends in proportions of vancomycin trough concentrations >15, 20, and
25 mg/l at an Australian tertiary hospital. Data are presented as percentages (%)
with a p-value from a Chi-squared test for trend over time.
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http://dx.doi.org/10.1016/j.ijid.2012.11.007incidence did not increase over time (p = 1.00). Despite increases
in local target ranges, increasing vancomycin minimum inhibi-
tory concentrations (MICs) in methicillin-resistant Staphylococ-
cus aureus in Australia have not been demonstrated to occur.7
Our data demonstrate that more aggressive vancomycin dosing
is accompanied by an increased proportion of levels that fall into
the nephrotoxic range. To offset this, target trough concentration
ranges based on an understanding of local vancomycin MIC
distributions should be considered. More frequent therapeutic
dose monitoring may also be of beneﬁt. Leu et al. neatly
demonstrated that nomogram-based dosing results in more
frequent attainment of target concentrations, equal clinical
effectiveness, and a potentially lower incidence of nephrotoxicity
compared with conventional dosing strategies. Another recent
publication has demonstrated similar ﬁndings.8
In conclusion, higher target vancomycin concentrations and the
difﬁculty of maintaining concentrations within these ranges are
placing patients at an increased risk of nephrotoxicity. Nomogram-
based dosing strategies that incorporate local MIC data offer a
practical solution to this problem.
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